These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35645805)

  • 101.
    Yu X; Zhu X; Zhang L; Qin JJ; Feng C; Li Q
    Front Pharmacol; 2022; 13():883581. PubMed ID: 35645805
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Redifferentiation of radioiodine-refractory thyroid cancers.
    Buffet C; Wassermann J; Hecht F; Leenhardt L; Dupuy C; Groussin L; Lussey-Lepoutre C
    Endocr Relat Cancer; 2020 May; 27(5):R113-R132. PubMed ID: 32191916
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
    Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
    Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
    Oncologist; 2024 May; ():. PubMed ID: 38760956
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and
    Anekpuritanang T; Uataya M; Claimon A; Laokulrath N; Pongsapich W; Pithuksurachai P
    Onco Targets Ther; 2021; 14():3959-3969. PubMed ID: 34234465
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Functional Radionuclide Imaging, In-Vitro Radioiodine Uptake Estimation and RT-PCR in the Evaluation of Sodium Iodide Symporter (NIS) Expression and Functionality in Breast Cancer: A Pilot Study.
    Joseph JK; Patel RB; Damle AA; Nair N; Badwe RA; Basu S
    Indian J Surg Oncol; 2013 Mar; 4(1):80-91. PubMed ID: 24426705
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Safety and efficacy of Prunella vulgaris preparation in adjuvant treatment of thyroid nodules: A meta-analysis.
    Han Q; Xu N; Chen B; Wu W; Sheng L
    Medicine (Baltimore); 2021 Oct; 100(41):e27490. PubMed ID: 34731129
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer
    Lin CL; Tsai ML; Chen YH; Liu WN; Lin CY; Hsu KW; Huang CY; Chang YJ; Wei PL; Chen SH; Huang LC; Lee CH
    Biomol Ther (Seoul); 2021 Sep; 29(5):551-561. PubMed ID: 34031270
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
    CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
    Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
    Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cancer statistics for adolescents and young adults, 2020.
    Miller KD; Fidler-Benaoudia M; Keegan TH; Hipp HS; Jemal A; Siegel RL
    CA Cancer J Clin; 2020 Nov; 70(6):443-459. PubMed ID: 32940362
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods.
    Bahmani A; Tanzadehpanah H; Hosseinpour Moghadam N; Saidijam M
    Mol Divers; 2021 May; 25(2):949-965. PubMed ID: 32297121
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
    Ferlay J; Colombet M; Soerjomataram I; Mathers C; Parkin DM; Piñeros M; Znaor A; Bray F
    Int J Cancer; 2019 Apr; 144(8):1941-1953. PubMed ID: 30350310
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
    CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Dose- and time-dependent pharmacokinetics of apigenin trimethyl ether.
    Elhennawy MG; Lin HS
    Eur J Pharm Sci; 2018 Jun; 118():96-102. PubMed ID: 29574080
    [TBL] [Abstract][Full Text] [Related]  

  • 117. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
    [TBL] [Abstract][Full Text] [Related]  

  • 118. A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
    Chow LQ; Santana-Davila R; Pantel A; Roth M; Anderson LN; Failor A; Doot R; Mankoff D
    PLoS One; 2017; 12(6):e0178325. PubMed ID: 28662033
    [TBL] [Abstract][Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.